Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
Avant Technologies Inc. logo

OTC · AVAI

Avant Technologies Inc.

Technology · Software - Application

$0.13

Up+$0.00 (+0.00%)

Updated Aug 15, 2026, 3:20 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
43.49M
P/E ratio
-39.42
Dividend yield
0.00%
52-week range
$0.25 – $0.83
Volume
294.37K
Avg. volume
97.6K

Price performance

AVAI price history

1M range · 0 trading sessions · Daily adjusted prices

AVAI does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AVAI news

The latest Smart Investors Daily articles mentioning AVAI.

Stock researchCompany · Overview

AVAI research

Overview

Company profile and research snapshot.

Company profile

AVANT TECHNOLOGIES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 21, 2026

A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.

Yahoo · Jul 21, 2026

Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy

Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that, together with its joint venture partner Austrianova, it has successfully concluded negotiations and reached agreement on the terms of a collaboration with a premier, internationally acclaimed, partner to provide insulin-producing cells for Insulinova's groundbreaking diabetes therapy.

Yahoo · Feb 11, 2026

Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website

Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced the completion of its corporate name change to Avaí Bio, Inc. (OTCQB:AVAI). The rebranding, effective today, February 11, 2026, reflects the Company's sharpened focus on advancing transformative treatments for type 1 and insulin-dependent type 2 diabetes, age-related diseases, and healthy longevity t

prnewswire.com · Dec 9, 2025

Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival

LAS VEGAS , Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced a newly published study from the Mayo Clinic reinforces the critical role of the "longevity protein" α-Klotho in vascular health and aging. The research, appearing in the Journal of the American Heart Association, demonstrates a strong association between declining α-Klotho levels and arterial stiffness, endothelial dysfunction, vascular calcification, and significantly reduced patient survival.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By